

Professor Barbara Casadei
Past Chair of the
Council on Basic Cardiovascular Science

Core Facilities
Head: Assoc. Univ. Prof. Dr. Johann Wojta

Reply to: Johann Wojta
E-Mail: johann.wojta@meduniwien.ac.at
Telephone: +43 (0)1 404000 - 73500
Fax: +43 (0)1 404000 - 73586

Vienna, 06.05.2016

Re: Application for the position of Secretary on the Council on Basic Cardiovascular Science

Dear Professor Casadei, dear members of the Council on Basic Cardiovascular Science,

the purpose of this letter is to formally apply for the position of Secretary on the Council on Basic Cardiovascular Science. Following I will describe briefly my motivation to do so and why I think I am well qualified to take up this position.


For the last two years I had the privilege and the pleasure to serve on the Council as a representative of the ESC Working Group on Thrombosis. Not only did I enjoy very much working with the members of the Council on a personal level but I also was impressed by the importance and relevance of the work of the Council to foster and support basic and translational research within the community of the ESC. As someone coming from a basic research background, who later on in my career moved closer to the clinical setting, I was always extremely interested in these areas of science. This interest is also reflected by my publication record, which includes publications that cover basic, translational and clinical research of cardiovascular medicine. I should also emphasize that I have also striven to support and foster young researchers with an interest in basic cardiovascular science be it locally in Austria as a Nucleus member and also as the Chair of the Working Group on Cardiovascular Biology and Thrombosis Research of the Austrian Society of Cardiology or on an international level as a member of the Nucleus of the ESC Working Group on Thrombosis. Thus I feel that the activities set by the Council on Basic Cardiovascular Science to foster young cardiovascular scientists through competitive awards and scholarships are of particular importance.

In that respect the biennial meeting Frontiers in Cardiovascular Biology - FCVB - is a flagship of the Council on Basic Cardiovascular Science to promote basic cardiovascular research within the community and in particular amongst young researchers. Therefore I was greatly honoured when the members of the Council on Basic Cardiovascular Science appointed me as Chair of the FCVB 2018 in Vienna. I see this appointment as a serious and challenging commitment and as a great opportunity to further successfully promote and strengthen basic cardiovascular science in Europe.

With all that said I hope that you will support my application for the position of Secretary on the Council on Basic Cardiovascular Science. I am convinced that I have ample experience for this position and if given the opportunity I am more than ready to devote significant time and effort to the highly important task to further

promote, support and strengthen the area of basic science and research in cardiovascular medicine within the ESC and Europe together with the distinguished colleagues on the Council on Basic Cardiovascular Science.

Yours sincerely



Johann Wojta, PhD

CURRICULUM VITAE

Name: Johann WOJTA

Address: A-1090 Vienna, Zimmermannngasse 1A/11

Date of Birth: March 28, 1957

Place of Birth: Vienna, Austria

Personal Status: Married to Sonja WOJTA-HIEBL; two children: Julia, born 29.6.1986; Manuel, born 2.2.1990

Education:
1967-1975 High School
1981 Ph.D. University of Vienna (Zoology)
(Thesis: Investigation on the possible importation of mosquito-borne arboviruses by migrating birds to Central Europe)

Postdoctoral Training:
1983-1985 Assistant Professor, Department of Medical Physiology, University of Vienna, Austria
1986-1988 Postdoctoral fellow, Department of Pathology, Vanderbilt University, Nashville, TN, USA
1989-1991 Assistant Professor, Department of Medical Physiology, University of Vienna, Austria
1991-1993 Senior Scientist, Department of Diagnostic Haematology, Royal Melbourne Hospital, Victoria, Australia
1993-1996 Assistant Professor, Department of Medical Physiology, University of Vienna

Academic position:
1990 Habilitation, Dozent of Medical Physiology, Department of Medical Physiology University of Vienna
1997-1999 Associate Professor of Medical Physiology, Department of Vascular Biology and Thrombosis Research University of Vienna
1999-present Associate Professor of Medical Physiology, Department of Internal Medicine II, Medical University of Vienna
1999-present Head of Research, Department of Internal Medicine II Medical University Vienna
2007-2009 Head of the Department of Physiology, Medical University of Vienna
2008 Guest scientist at the Institut Catala de Ciencies Cardiovasculars, Hospital de Sant Pau, Barcelona, Spain
2009-present Coordinator of the Ludwig Boltzmann Cluster for Cardiovascular Research; information under <http://www.meduniwien.ac.at/cvd/StartseiteLBG.htm>
2010-present Coordinator of the Anna Spiegel Center for Translational Research, Medical University of Vienna; information under <http://www.meduniwien.ac.at/orgs/index.php?id=1041&L=0>
2013-present Head of Core Facilities, Medical University of Vienna; information under <http://corefacilities.meduniwien.ac.at/?L=1>

Teaching:

1984-2005	Practical Course in Medical Physiology
1991-1994	Introductory lecture to the Practical Course in Medical Physiology
1993-present	Introduction into Research Techniques
1997-2003	Physiology for Dieticians
1997-present	Physiological case studies
2002-present	New medical curriculum, block 2: The human body, physiology; block 7: SSM1, Science and medicine; block 12: Physiology of respiration; block 17: SSM2, Methods of science in medicine; block 24: SSM3, diploma thesis
2003-present	Anatomy, physiology and medical terminology for Pharmacologists
1994-2005	60-100 examinations in Medical Physiology per year
2009-present	Coordinator of the N790 Doctoral Program "Cardiovascular and pulmonary disease"; information under http://www.meduniwien.ac.at/studienabteilung/content/studium-lehre/studienangebot/n790/thematic-programs/cardiovascular-and-pulmonary-disease/

Grants:

1987	Austrian Fund for the Promotion of Scientific Research: Schroedinger Grant
1989	Austrian Fund for the Promotion of Scientific Research, P7617-M: "Heterogeneity of the fibrinolytic system of endothelial cells: cause for different expression of factors of the fibrinolytic system in human endothelial cells"
1991	The National Heart Foundation of Australia, G91M3395: "Interaction of human endothelial and smooth muscle cells: regulation of fibrinolysis"
1992	Victor Hurley Medical Research Fund: "Cocultivated human endothelial and smooth muscle cells as a model to study invasion and metastasis"
1993	Austrian Fund for the Promotion of Scientific Research, P9479-M: "Regulation of the urokinase receptor on vascular cells"
1995	Austrian Fund for the Promotion of Scientific Research, P 10605-M: "Possible role of hepatocyte growth factor in the regulation of proteolysis. Implications of the fibrinolytic and coagulation pathways"
1995	Austrian Fund for the Promotion of Scientific Research, Project Programme Grant F 509: "Microvascular injury and repair"
2000	Austrian Heart Fund: "Chlamydia and vascular cells. Their role in endothelial dysfunction and smooth muscle cell proliferation, two crucial events in the development of atherosclerosis."
2000	International Cardura Competitive Awards Program: "Effect of doxazosin on the fibrinolytic profile of human vascular cells."
2001	International Cardura Competitive Awards Program: "The effect of doxazosin on norepinephrine-regulated expression of candidate genes in human endothelial cells involved in plaque destabilization."
2002	Austrian Heart Fund: "Helicobacter pylori, mycoplasma pneumoniae, cytomegalovirus, Epstein Barr virus and herpes simplex virus in carotid atherosclerosis: A comparison of their respective presence in atherosclerotic plaque, healthy vessels and circulating leukocytes from the same individuals. A direct evaluation of "pathogen burden".
2003	Fund of the Austrian National Bank: "Crosstalk between cardiac myocytes and bone marrow cells in vitro. Possible implications for stem cell technology of ischaemic heart disease."

2004	Austrian Heart Fund: "Stress induced plaque rupture. Do catecholamines play a role?"
2005	Austrian Fund for the Promotion of Scientific Research, Joint Research Project S9409-B11: "Angiogenesis in disease"
2006	Ludwig Boltzmann Cluster for Cardiovascular Research
2008	Jubiläumsfonds der Österreichischen Nationalbank: "Clinical investigations on a role for the antiangiogenic protein pigment epithelium-derived factor in the development and progression of cardiovascular disease."
2008	Austrian Heart Fund: "Role of glycoprotein 130 cytokine family in the regulation of vascular endothelial growth factor production in human vascular smooth muscle cells and its possible counteraction by interferon."
2009-2012	Ludwig Boltzmann Cluster for Cardiovascular Research
2013-2016	Ludwig Boltzmann Cluster for Cardiovascular Research
2014-2018	Austrian Fund for the Promotion of Scientific Research, SFB F54-B21: "Cellular mediators linking inflammation and thrombosis"

Awards:

1989	Hoechst-Award
1992	Harry Lovat Fraser- Kathleen Fraser Research Award, The National Heart Foundation of Australia
1996	Career Development Award of the City of Vienna
2000	Cardura Award
2001	Cardura Award
2003	Austrian Cardiologic Society
2006	Teacher of the Month, Medical University of Vienna

Publications:

Currently 259 papers in peer reviewed journals with a total impact factor of >1600 according to https://www.researchgate.net/profile/Johann_Wojta and <http://www.ncbi.nlm.nih.gov/pubmed/?term=wojta+j> and a Hirsh-index of 42 according to http://apps.webofknowledge.com/CitationReport.do?product=UA&search_mode=CitationReport&SID=X1s8tAYNGIc8N8Ok8H7&page=1&cr_pqid=1&viewType=summary

Referee:

Reviewer for peer-reviewed journals such as "Circulation", "Journal of the American College of Cardiology", "Blood", "European Heart Journal", "Cell Reports", "Journal of Immunology", "Journal of Cell Science", "Arteriosclerosis, Thrombosis and Vascular Biology", "Oncogene", "Journal of Cellular and Molecular Medicine", "American Journal of Pathology", "Stroke", "Diabetologia", "Journal of Thrombosis and Haemostasis", "Journal of Neuroinflammation", "Cardiovascular Research", "Thrombosis Haemostasis", "Journal of Molecular and Cellular Cardiology", "International Journal of Biochemistry and Cell Biology", "American Journal of Physiology", "Microbes and Infection", "Atherosclerosis", "Microcirculation", "Expert Opinion on Therapeutic Targets", "British Journal of Pharmacology", "European Journal of Clinical Investigation", "Biochemical Pharmacology", "Pharmacological Research", "Annals of Hematology", "Diabetes/Metabolism Research and Reviews", "Biochimica Biophysica Acta", "Regulatory Peptides", "Planta Medica", "Fibrinolysis and Proteolysis", "Thrombosis Research", "Blood Coagulation and Fibrinolysis", "Journal of Biomedical Materials Research Part A", "Vascular Pharmacology", "Current Cancer Drug Targets", "Obesity" and many others.

Reviewer for national and international grants such as the Austrian Fund for the Promotion of Scientific Research, the Fund of the Austrian National Bank, the Agencia de Gestio d'Ajuts Universitaris I de Recerca in Spain, the Fundacio La Marato de TV3 in Spain, the Belgian Federal Science Policy Office, the Croatian Research Foundation, the Swiss National Science Foundation, the Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale des Ministero dell' Universita e della Ricerca Scientifica e Tecnologica, Italia, the Health and Medical Research Fund under the Government of the Hong Kong SAR, the National Science Center of Poland, the Slovenian Research Agency, the Health Research Council of New Zealand, the Academy of Medical Sciences of the UK and for the Quality of Life and Management of Living Resources Programme, European Commission.

Memberships, Societies and Congresses:

1993	Member of The Society for Thrombosis- and Haemostasis Research
1994	Member of The Council on Thrombosis of The American Heart Association
1994	Member of The International Society for Fibrinolysis and Proteolysis
1996	Founding President of The Austrian Vascular Biology Organisation
1999-present	Secretary of The Austrian Vascular Biology Organisation
2000	Austrian Cardiologic Society
2001	International Society of Thrombosis and Haemostasis
2001-2003	Chairman of the Working Group "Experimental Cardiology" of the Austrian Cardiologic Society
2005-2007	Chairman of the Working Group "Arteriosclerosis, Thrombosis and Vascular Biology" of the Austrian Cardiologic Society
2009-2011	Chairman of the Working Group "Experimental Cardiology" of the Austrian Cardiologic Society
2008	President of the XIX th International Congress on Fibrinolysis and Proteolysis
2010	Chairman Elect of the International Congress on Fibrinolysis and Proteolysis
2010-present	Nucleus Member of the Working Group on Thrombosis of the European Society of Cardiology
2012	Chairman of the International Congress on Fibrinolysis and Proteolysis
2012	President of the Eurothrombosis Summit of the European Society of Cardiology
2012-2014	Chairman of the International Society for Fibrinolysis and Proteolysis
2014	Vice-President of the 58 th Meeting of the Society of Thrombosis and Haemostasis Research
2014-2016	Chairman of the Working Group "Cardiovascular Biology and Thrombosis Research" of the Austrian Cardiologic Society
2015-present	Member of the Council on Basic Cardiovascular Research of the European Society of Cardiology
2018	Chairman of the 5 th edition of Frontiers in Cardiovascular Biology

Miscellaneous:

1995-present	Organisation and administration of clinical elective-programme with 2 Australian universities (Monash University, University of Wollongong). 10 to 20 students per year participate in this programme. Information under: www.meduniwien.ac.at/australia
2015-present	Member of the Ethics Committee on Animal Research, Medical University of Vienna

LIST OF PUBLICATIONS

1. J. Wojta, C. Korninger, J. Kirchheimer, E. Hattey, L. Turcu, B.R. Binder: Anwendung monoklonaler Antikörper in der Fibrinolyse-diagnostik. **Wien. Klin. Wochenschr.** **97**: 244-248, 1985
2. J. Wojta, J.C. Kirchheimer, L. Turcu, G. Christ, B.R. Binder: Monoclonal antibodies against high molecular weight urinary urokinase: Application for affinity purification of urinary prourokinase. **Thromb. Haemost.** **55**: 347-351, 1986
3. C. Korninger, W. Speiser, J. Wojta, B.R. Binder: Sandwich ELISA for t-PA antigen employing a monoclonal antibody. **Thromb. Res.** **41**: 527-535, 1986
4. J. Wojta, L. Turcu, O.F. Wagner, C. Korninger, B.R. Binder: Evaluation of fibrinolytic capacity by a combined system for t-PA antigen and t-PA function using monoclonal anti-t-PA antibodies. **J. Lab. Clin. Med.** **109**: 665-671, 1987
5. E. Hattey, J. Wojta, B.R. Binder: Monoclonal antibodies against plasminogen and alpha-2-antiplasmin: Binding to native and modified antigens. **Thromb. Res.** **45**: 485-495, 1987
6. J.C. Kirchheimer, J. Wojta, G. Christ, B.R. Binder: Proliferation of a human epidermal tumor cell line stimulated by urokinase. **FASEB J.** **1**: 125-128, 1987
7. W. Speiser, J. Wojta, C. Korninger, J.C. Kirchheimer, J. Zazgornik, B.R. Binder: Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. **Kidney Int.** **32**: 280-283, 1987
8. J.C. Kirchheimer, J. Wojta, G. Hienert, G. Christ, M.E. Heger, H. Pflüger, B.R. Binder: Effect of urokinase on the proliferation of primary cultures of human prostatic cells. **Thromb. Res.** **48**: 291-298, 1987
9. J.C. Kirchheimer, I. Resch, G. Christ, J. Wojta, B.R. Binder: Effect of the cyanogen-bromide-2 fragment of fibrinogen on plasminogen activation by single chain urokinase type plasminogen activator. **Eur. J. Biochem.** **166**: 393-397, 1987
10. J. Wojta, J.C. Kirchheimer, M.G. Peska, B.R. Binder: Effect of caffeine ingestion on plasma fibrinolytic potential. **Thromb. Haemost.** **59**: 337-338, 1988
11. J. Wojta, R.L. Jones, B.R. Binder, R.L. Hoover: Reduction in PO₂ decreases the fibrinolytic potential of cultured bovine endothelial cells derived from pulmonary arteries and lung microvasculature. **Blood** **71**: 1703-1706, 1988
12. K. Bartha, J. Wojta, O.F. Wagner, B.R. Binder: Comparison of fibrinolytic activities of human and bovine endothelial cells. **Am. J. Physiol.** **254**: R885-R890, 1988
13. J.C. Kirchheimer, J. Wojta, G. Christ, G. Hienert, B.R. Binder: Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. **Carcinogenesis** **9**: 2121-2123, 1988

14. K. Huber, J. Wojta, J.C. Kirchheimer, D. Ermler, B.R. Binder: Plasminogen activators and plasminogen activator inhibitors in malignant and nonmalignant ascitic fluid. **Eur. J. Clin. Invest.** **18**: 595-599, 1988
15. F. Ehrenreich, E. Hattey, J. Wojta, B.R. Binder: Effect of anti plasminogen monoclonal antibodies on whole blood clot lysis. **Haemostasis** **18 Suppl. 1**: 99-107, 1988
16. J. Wojta, R.L. Hoover, T.O. Daniel: Vascular origin determines plasminogen activator expression in human endothelial cells: Renal endothelial cells produce large amounts of scu-PA. **J. Biol. Chem.** **264**: 2846-2852, 1989
17. J. Wojta, R. Beckmann, L. Turcu, O.F. Wagner, A.J. van Zonneveld, B.R. Binder: Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue type plasminogen activator (t-PA). **J. Biol. Chem.** **264**: 7957-7961, 1989
18. J. Wojta, B.R. Binder, K. Huber, R.L. Hoover: Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with two chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. **Thromb. Haemost.** **61**: 289-293, 1989
19. M. Geiger, K. Huber, J. Wojta, L. Stingl, F. Espana, J.H. Griffin, B.R. Binder: Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo. **Blood** **74**: 722-728, 1989
20. J.C. Kirchheimer, J. Wojta, G. Christ, B.R. Binder: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. **Proc. Natl. Acad. Sci. USA** **86**: 5424-5428, 1989
21. F.U. Garcia, J. Wojta, K.N. Broadley, J.M. Davidson, R.L. Hoover: Bartonella bacilliformis stimulates endothelial cells in vitro and is angiogenic in vivo. **Amer. J. Pathol.** **136**: 1125-1135, 1990
22. J. Wojta, M. Holzer, P. Hufnagl, G. Christ, R.L. Hoover, B.R. Binder: Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. **Amer. J. Pathol.** **139**: 911-919, 1991
23. J. Wojta, H. Zoellner, M. Gallicchio, J.A. Hamilton, K. McGrath: γ -Interferon counteracts interleukin-1 α stimulated expression of urokinase type plasminogen activator in human endothelial cells in vitro. **Biochem. Biophys. Res. Com.** **188**: 463-469, 1992
24. F.U. Garcia, J. Wojta, R.L. Hoover: Interactions between live Bartonella bacilliformis and endothelial cells. **J. Infect. Dis.** **165**: 1138-1141, 1992
25. G. Christ, J. Wojta, B.R. Binder: Distribution of smooth muscle cell derived urokinase in cocultures with endothelial cells. **Fibrinolysis** **6, Suppl. 4**: 139-143, 1992
26. O.F. Wagner, G. Christ, J. Wojta, H. Vierhapper, S. Parzer, P.J. Nowotny, B. Schneider, W. Waldhäusl, B.R. Binder: Polar secretion of endothelin-1 by cultured endothelial cells. **J. Biol. Chem.** **267**: 16066-16069, 1992

27. J.A. Hamilton, I.K. Campbell, J. Wojta, D. Cheung: Plasminogen activators and their inhibitors in arthritic disease. **Ann. N.Y. Acad. Sci.** **667**: 87-100, 1992
28. J.A. Hamilton, D. Cheung, E.L. Filonzi, D.S. Piccoli, J. Wojta, M. Gallicchio, K. McGrath, K. Last: Independent regulation of plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in human synovial fibroblasts. **Arthr. Rheum.** **35**: 1526-1534, 1992
29. J. Wojta, M. Gallicchio, H. Zoellner, E.L. Filonzi, J.A. Hamilton, K. McGrath: Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells. **Blood** **81**: 3285-3292, 1993
30. J. Wojta, M. Gallicchio, H. Zoellner, P. Hufnagl, K. Last, E.L. Filonzi, B.R. Binder, J.A. Hamilton, K. McGrath: Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. **Thromb. Haemost.** **70**: 469-474, 1993
31. H. Zoellner, J. Wojta, M. Gallicchio, K. McGrath, J.A. Hamilton: Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Comparison with plasminogen activator inhibitor-1 synthesis. **Thromb. Haemost.** **69**: 135-140, 1993
32. G. Christ, D. Seiffert, P. Hufnagl, A. Gessl, J. Wojta, B.R. Binder: Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells. **Blood** **81**: 1277-1283, 1993
33. P.G. Tipping, P. Davenport, M. Gallicchio, E.L. Filonzi, J. Apostolopoulos, J. Wojta: Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. **Amer. J. Pathol.** **143**: 875-885, 1993
34. J. Malliaros, S.R. Holdsworth, J. Wojta, J. Erlich, P.G. Tipping: Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. **Kidney Int.** **44**: 557-564, 1993
35. J.J. Liu, D. Casley, J. Wojta, M. Gallicchio, R. Dauer, B.F. Buxton, C.I. Johnston: Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a "natural factor" in cultured human endothelial cells. **J. Hypertension** **11**: 977-982, 1993
36. J.A. Hamilton, G.A. Whitty, J. Wojta, M. Gallicchio, K. McGrath, G. Ianches: Regulation of plasminogen activator inhibitor-1 levels in human monocytes. **Cell. Immunol.** **152**: 7-17, 1993
37. J.A. Hamilton, G.A. Whitty, H. Stanton, J. Wojta, M. Gallicchio, K. McGrath, G. Ianches: Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor stimulate synthesis of plasminogen activator inhibitors by human monocytes. **Blood** **82**: 3616-3621, 1993

38. J.A. Hamilton, J. Wojta, M. Gallicchio, K. McGrath, E.L. Filonzi: Contrasting effects of TGF- β and IL-1 on the regulation of plasminogen activator inhibitors in human synovial fibroblasts. **J. Immunol.** **151**: 5154-5161, 1993
39. J. Wojta, H. Zoellner, M. Gallicchio, E.L. Filonzi, J.A. Hamilton, K. McGrath: Interferon- α 2 counteracts interleukin-1 α stimulated expression of urokinase-type plasminogen activator in human foreskin microvascular endothelial cells in vitro. **Lymphokine Cytokine Res.** **13**: 133-138, 1994
40. J. Wojta, T. Nakamura, A. Fabry, P. Hufnagl, R. Beckmann, K. McGrath, B.R. Binder: Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. **Blood** **84**: 151-157, 1994
41. J.J. Liu, D. Casley, J. Wojta, M. Gallicchio, R. Dauer, C.I. Johnston, B.F. Buxton: Effects of calcium-and ET_A-receptor antagonist on endothelin-induced vasoconstriction and levels of endothelin in the human internal mammary artery. **Clin. Exp. Pharmacol. Physiol.** **21**: 49-57, 1994
42. M. Gallicchio, S. Argyriou, G. Ianches, E.L. Filonzi, H. Zoellner, J.A. Hamilton, K. McGrath, J. Wojta: Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells. **Arterioscl. Thromb.** **14**: 815-823, 1994
43. W. Zhang, J. Wojta*, B.R. Binder: Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. **Arterioscl. Thromb.** **14**: 1040-1046, 1994
44. D.B. Al-Azhary, J. Wojta*, B.R. Binder: Fibrinolytic system of cultured rabbit aortic endothelial cells. **Thromb. Res.** **75**: 559-568, 1994
45. I.K. Campbell, J. Wojta, U. Novak, J.A. Hamilton: Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor- α and up-regulation by transforming growth factor- β and basic fibroblast growth factor. **Biochim. Biophys. Acta** **1226**: 277-285, 1994
46. J.C. Zhang, J. Wojta*, B.R. Binder: Growth and fibrinolytic parameters of human umbilical vein endothelial cells seeded onto cardiovascular grafts. **J. Thor. Cardiovasc. Surg.** **109**: 1059-1065, 1995
47. W.J. Zhang, A. Fabry, J. Wojta*, B.R. Binder: Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured human pulmonary artery endothelial cells and human skin microvascular endothelial cells. **Fibrinolysis** **9, Suppl. 1**: 133-139, 1995
48. M. Gallicchio, J. Wojta, J.A. Hamilton, K. McGrath: Regulation of plasminogen activator inhibitor type 1 in cultured smooth muscle cells by interleukin 1 α and tumor necrosis factor- α . **Fibrinolysis** **9**: 145-151, 1995
49. H. Zoellner, E. Bielek, E. Vanyek, A. Fabry, J. Wojta, M. Höfler, B.R. Binder: Canalicular fragmentation of apoptotic human endothelial cells. **Endothelium** **4**: 177-188, 1996

50. K. Addo-Boadu, J. Wojta*, G. Christ, P. Hufnagl, H. Pehamberger, B.R. Binder: Azealic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. **Cancer Letters** **103**: 125-129, 1996
51. J.C. Zhang, A. Fabry, L. Paucz, J. Wojta*, B.R. Binder: Human fibroblasts downregulate plasminogen activator inhibitor type-1 in cultured human macrovascular and microvascular endothelial cells. **Blood** **88**: 3880-3886, 1996
52. M. Gallicchio, P. Hufnagl, J. Wojta, P. Tipping: IFN- γ inhibits thrombin and endotoxin induced plasminogen activator inhibitor type 1 in human endothelial cells. **J. Immunol.** **157**: 2610-2617, 1996
53. H. Zoellner, M. Höfler, R. Beckmann, P. Hufnagl, E. Vanyek, E. Bielek, J. Wojta, A. Fabry, S. Lockie, B.R. Binder: Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. **J. Cell Sci.** **109**: 2571-2580, 1996
54. M. Baghestanian, R. Hofbauer, H.G. Kress, J. Wojta, A. Fabry, B.R. Binder, C. Kaun, M.R. Müller, M.R. Mehrabi, S. Kapiotis, S. Sengoelge, M. Ghannadan, K. Lechner, P. Valent: Thrombin augments vascular cell-dependent migration of human mast cells. **Thromb. Haemost.** **77**: 577-584, 1997
55. W.J. Zhang, J. Wojta*, B.R. Binder: Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin -induced lethality in mice in vivo. **Arterioscl. Thromb. Vasc. Biol.** **17**: 723-730, 1997
56. G. Christ, P. Hufnagl, C. Kaun, G. Mundigler, G. Laufer, K. Huber, J. Wojta, B.R. Binder: Antifibrinolytic properties of the vascular wall: Dependence on the history of smooth muscle cell doublings in vitro and in vivo. **Arterioscl. Thromb. Vasc. Biol.** **17**: 465-474, 1997
57. W.J. Zhang, J. Wojta*, B.R. Binder: Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: Astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression. **J. Vasc. Res.** **34**: 273-280, 1997
58. W. Tschugguel, R. Zeillinger, E. Tantscher, Z. Zhegu, K. Cerwenka, A. Fabry, J. Wojta, W. Knogler, J.C. Huber: Estrogen does not induce the calcium dependent nitric oxide synthase in cultured human uterine endothelial and myometrial smooth muscle cells. **J. Vasc. Res.** **34**: 281-288, 1997
59. W.J. Zhang, J. Wojta*, B.R. Binder: Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery. **Cell. Molec. Biol.** **43**: 581-587, 1997
60. W.J. Zhang, T. Bammer, B.R. Binder, J. Wojta*: Effect of endothelin on the regulation of the fibrinolytic system of cultured human vascular smooth muscle cells. **Fibrinol. Proteol.** **11**: 245-250, 1997

61. J. Pammer, W. Weninger, M. Mildner, M. Burian, J. Wojta, E. Tschachler: Vascular endothelial growth factor is constitutively expressed in normal salivary glands and is secreted in the saliva of healthy individuals. **J. Pathol.** **186**: 186-191, 1998
62. K. Ruzicka, J. Wojta, O. Artemiou, T. Birsan, P. Quehenberger, S. Kapiotis, R. Hofbauer, W. Speiser: Human endothelial cells do not exert heparin like accelerating effects on thrombin-antithrombin-complex formation. **Life Sciences** **63**: 1493-1503, 1998
63. J.C. Zhang, Q.R. Ruan, L. Paucz, A. Fabry, B.R. Binder, J. Wojta*: Stimulation of tissue factor expression in human microvascular and macrovascular endothelial cells by cultured vascular smooth muscle cells in vitro. **J. Vasc. Res.** **36**: 126-132, 1999
64. R. Roller, S. Janisch, V. Carroll, E. Kvas, E. Pilger, B.R. Binder, J. Wojta*: Changes in fibrinolytic system in patients with peripheral arterial occlusive disease undergoing percutaneous transluminal angioplasty. **Thromb. Res.** **94**: 241-247, 1999
65. J. Wojta*, C. Kaun, J.M. Breuss, Y. Koshelnick, R. Beckmann, E. Hattey, M. Mildner, W. Weninger, T. Nakamura, E. Tschachler, B.R. Binder: Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. **Lab. Invest.** **79**: 427-438, 1999
66. A. Obermair, A. Obruca, A. Kaider, M. Pohl, A. Vales, S. Leodolter, J. Wojta, W. Feichtinger: Vascular endothelial growth factor and its receptors in male fertility. **Fertil. Steril.** **72**: 269-275, 1999
67. M. Krebs, P. Uhrin, A. Vales, M.J. Prendes-Garcia, J. Wojta, M. Geiger, B.R. Binder: Protein C inhibitor is expressed in keratinocytes of human skin. **J. Invest. Dermatol.** **113**: 32-37, 1999
68. J. Pammer, W. Weninger, J. Ban, J. Wojta, E. Tschachler: The cell death regulatory protein Bak is expressed in endothelial cells in inflamed tissues and is induced by IFN- γ in vitro. **Biochem. Biophys. Res. Com.** **264**: 139-143, 1999
69. M. Gottsauner-Wolf, P. Wexberg, K. El-Rabadi, J. Wojta, G. Maurer, K. Huber: Atherosklerose: Eine Infektionskrankheit? **Wien. Klin. Wochenschr.** **112**: 253-259, 2000
70. R. Roller, S. Janisch, E. Kvas, W.J. Schnedl, B.R. Binder, J. Wojta, C. Korninger: Smooth muscle cell migration promoting activity of plasma predicts restenosis in patients with peripheral arterial occlusive disease undergoing angioplasty. **Thromb. Haemost.** **84**: 1113-1116, 2000
71. Q.R. Ruan, W.J. Zhang, P. Hufnagl, C. Kaun, B.R. Binder, J. Wojta*: Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF- κ B pathway. **J. Vasc. Res.** **38**: 13-19, 2001

72. A. Anvari, E. Schuster, M. Gottsauner-Wolf, J. Wojta, K. Huber: PAI-1 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. **Thromb. Res. 103**: 103-107, 2001
73. K. Huber, G. Christ, J. Wojta, D. Gulba: Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. **Thromb. Res. 103 Suppl. 1**: S7-S19, 2001
74. M. Nikfardjam, S. Graf, S. Hornykewycz, G. Zorn, R. Huber-Beckmann, J. Wojta, K. Huber: Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. **Thromb. Res. 103 Suppl. 1**: S35-S39, 2001
75. F. Wiesbauer, C. Kaun, G. Zorn, G. Maurer, K. Huber, J. Wojta*: HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: A comparative study using different statins. **Brit. J. Pharmacol. 135**: 284-292, 2002
76. P. Valent, M. Baghestanian, H.C. Bankl, C. Sillaber, W.R. Sperr, J. Wojta, B.R. Binder, K. Lechner: New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. **Thromb. Haemost. 87**: 786-790, 2002
77. W.S. Speidl, S. Graf, S. Hornykewycz, M. Nikfardjam, A. Niessner, G. Zorn, J. Wojta, K. Huber: C-reactive protein, determined by use of a new high sensitive assay system, in the prediction of coronary events in patients with premature coronary artery disease. **Am. Heart J. 144**: 449-455, 2002
78. J. Wojta*, C. Kaun, G. Zorn, M. Ghannadan, A.W. Hauswirth, W.R. Sperr, G. Fritsch, D. Printz, B.R. Binder, G. Schatzl, J. Zwirner, G. Maurer, K. Huber, P. Valent: C5a stimulates production of plasminogen activator inhibitor-1 (PAI-1) in human mast cells and basophils. **Blood 100**: 517-523, 2002
79. M.R. Mehrabi, N. Serbecic, F. Tamaddon, C. Kaun, K. Huber, R. Pacher, T. Wild, G. Mall, J. Wojta, H. D. Glogar: Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. **Cardiovasc. Res. 56**: 214-224, 2002
80. M. Prager, Z. Türel, W.S. Speidl, G. Zorn, C. Kaun, A. Niessner, G. Heinze, I. Huk, G. Maurer, K. Huber, J. Wojta*: *Chlamydia pneumoniae* in carotid artery atherosclerosis: A comparison of its presence in the atherosclerotic plaque, in healthy vessels and in circulating leukocytes from the same individuals. **Stroke 33**: 2756-2761, 2002
81. K. Macfelda, T. Weiss, C. Kaun, J.M. Breuss, B. Kapeller, G. Zorn, U. Oberndorfer, M. Voegelé-Kadletz, R. Huber-Beckmann, R. Ullrich, B.R. Binder, U.M. Losert, G. Maurer, R. Pacher, K. Huber, J. Wojta*: Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1 α , tumor necrosis factor- α , transforming growth factor- β and oncostatin M in human cardiac myocytes. **J. Mol. Cell. Cardiol. 34**: 1681-1691, 2002
82. M.R. Mehrabi, K. Huber, N. Serbecic, T. Wild, J. Wojta, F. Tamaddon, A. Morgan, R. Ullrich, H.D. Glogar: Elevated homocysteine serum level is associated with low enrichment

- of homocysteine in coronary arteries of patients with coronary artery disease. **Thromb. Res. 107**: 189-196, 2002
83. A. Schindl, H. Merwald, L. Schindl, C. Kaun, J. Wojta: Direct stimulatory effect of low-intensity 670 nm laser irradiation on human endothelial cell proliferation. **Brit. J. Dermatol. 148**: 334-336, 2003
84. S. Pfaffenberger, B. Devcic-Kuhar, K. El-Rabadi, M. Gröschl, W.S. Speidl, T.W. Weiss, K. Huber, E. Benes, G. Maurer, J. Wojta, M. Gottsauner-Wolf: 2MHz ultrasound enhances t-PA-mediated thrombolysis: Comparison of continuous versus pulsed ultrasound and standing versus travelling acoustic waves. **Thromb. Haemost. 89**: 583-589, 2003
85. M. Uchiba, K. Okajima, C. Kaun, B.R. Binder, J. Wojta: Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of leukocyte adhesion molecules *in vitro*. **Crit. Care Med. 31**: 1147-1153, 2003
86. G. Endler, A. Hamwi, R. Sunder-Plassmann, M. Exner, T. Vukovich, C. Mannhalter, J. Wojta, K. Huber, O. Wagner: Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women? **Clin. Chem. 49**: 1201-1204, 2003
87. A. Niessner, C. Kaun, G. Zorn, W. Speidl, Z. Türel, G. Christiansen, A.S. Pedersen, S. Birkelund, S. Simon, A. Georgopoulos, W. Graninger, R. de Martin, J. Lipp, B.R. Binder, G. Maurer, K. Huber, J. Wojta*: Polymorphic membrane proteins 20 and 21 of *Chlamydia pneumoniae* induce proinflammatory mediators in human endothelial cells *in vitro* by activation of the NF- κ B pathway. **J. Infect. Dis. 188**: 108-113, 2003
88. M.A. Gallicchio, C. Kaun, J. Wojta, B.R. Binder, L.A. Bach: Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells *in vitro*. **J. Cell. Physiol. 197**: 131-138, 2003
89. T.W. Weiss, W.S. Speidl, C. Kaun, G. Rega, C. Springer, K. Macfelda, U.M. Losert, S.L. Grant, M.L. Marro, A.D. Rhodes, A. Fürnkranz, J. Bialy, R. Ullrich, P. Holzmann, R. Pacher, G. Maurer, K. Huber, J. Wojta*: The glycoprotein 130 ligand oncostatin-m induces expression of vascular endothelial cell growth factor in human adult cardiac myocytes. **Cardiovasc. Res. 59**: 628-638, 2003
90. A. Niessner, S. Graf, M. Nikfardjam, W.S. Speidl, R. Huber-Beckmann, G. Zorn, J. Wojta, K. Huber: Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease - a 13-year follow-up. **Thromb. Haemost. 90**: 344-350, 2003
91. W.J. Zhang, P. Hufnagl, B.R. Binder, J. Wojta*: Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF- κ B activation and adhesion molecule expression. **Thromb. Haemost. 90**: 904-914, 2003
92. R. Schäfer, D. Abraham, P. Paulus, R. Blumer, M. Grimm, J. Wojta, S. Aharinejad: Impaired VE-cadherin/ β -catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. **Circulation 108**: 1585-1591, 2003

93. A. Weltermann, P. Fritsch, P.A. Kyrle, V. Schoenauer, G. Heinze, G. Christ, J. Wojta, K. Huber: Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. **Thromb. Res. 112**: 19-24, 2003
94. G. Endler, M. Exner, M. Raith, R. Marculescu, C. Mannhalter, L. Endler, J. Wojta, K. Huber, O.F. Wagner. The e-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2. **Thromb. Res. 112**: 47-50, 2003
95. W.S. Speidl, J. Wojta, K. Huber: Definition der akuten Koronarsyndrome und aktuelle Therapie des akuten Myokardinfarkts 2004. **Perfusion 17**: 277-283, 2004
96. M. Gyongyosi, D. Glogar, F. Weidinger, H. Domanovits, A. Laggner, G. Zorn, J. Wojta, K. Huber: Association between plasmin activation system and sonographic signs of plaque instability in patients with UA/NSTEMI. **Am. Heart J. 147**: 158-164, 2004
97. G. Endler, M. Exner, M. Schillinger, R. Marculescu, R. Sunder-Plassmann, M. Raith, N. Jordanova, J. Wojta, C. Mannhalter, O.F. Wagner, K. Huber: A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. **Thromb. Haemost. 91**: 155-161, 2004
98. C.W. Kopp, T. Hoelzenbein, S. Steiner, R. Marculescu, H. Bergmeister, D. Seidinger, I. Mosberger, C. Kaun, M. Cejna, R. Horvat, J. Wojta, G. Maurer, B.R. Binder, J.M. Breuss, R.C. Ecker, R. De Martin, E. Minar. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. **Blood 103**: 1653-1661, 2004
99. W.S. Speidl, W.G. Toller, C. Kaun, T.W. Weiss, S. Pfaffenberger, S.P. Kastl, A. Fürnkranz, G. Maurer, K. Huber, H. Metzler, J. Wojta*: Catecholamines potentiate lipopolysaccharide-induced expression of matrix metalloproteinase-1 and matrix metalloproteinase-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. **FASEB J. 18**: 603-605, 2004
100. A. Niessner, S. Hornykewycz, S. Graf, M. Nikfardjam, W.S. Speidl, P. Probst, G. Zorn, G. Maurer, J. Wojta, K. Huber: Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: Predictive value for a complicated course? **Blood Coagul. Fibrinol. 15**: 311-316, 2004
101. T.W. Weiss, M.R. Mehrabi, C. Kaun, G. Zorn, S.P. Kastl, W.S. Speidl, S. Pfaffenberger, G. Rega, H.D. Glogar, G. Maurer, R. Pacher, K. Huber, J. Wojta*: Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. **J. Mol. Cell. Cardiol. 36**: 539-546, 2004
102. B. Devcic-Kuhar, S. Pfaffenberger, L. Gherardini, C. Mayer, M. Gröschl, C. Kaun, E. Benes, E. Tschachler, K. Huber, G. Maurer, J. Wojta*§, M. Gottsauner-Wolf§: Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro. **Thromb. Haemost. 92**: 980-985, 2004

103. J. Pammer, C. Reinisch, C. Kaun, E. Tschachler, J. Wojta*: Inhibitor of differentiation/DNA binding protein Id1 is upregulated by fluvastatin in endothelial cells. **Endothelium 11**: 175-180, 2004
104. J. Wojta*, K. Huber, P. Valent: New aspects in Thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. **Pathophysiol. Haemost. Thromb. 33**: 438-441, 2004
105. M. Funk, G. Endler, R. Freitag, J. Wojta, K. Huber, C. Mannhalter, R. Sunder-Plassmann: CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. **Clin. Chem. 50**: 2395-2398, 2004
106. M. Gyongyosi, H. Domanovits, W. Benzer, M. Haugk, B. Heinisch, G. Sodeck, R. Hoedl, G. Gaul, G. Bonner, J. Wojta, A. Laggner, D. Glogar, K. Huber: Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion – results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. **Eur. Heart J. 25**: 2125-2133, 2004
107. M. Uchiba, K. Okajima, C. Kaun, J. Wojta, B.R. Binder: Inhibition of the endothelial cell activation by antithrombin *in vitro*. **Thromb. Haemost. 92**: 1420-1427, 2004
108. S. Pfaffenberger, B. Devcic-Kuhar, C. Kollmann, S.P. Kastl, C. Kaun, W.S. Speidl, T.W. Weiss, R. Ullrich, H. Sochor, C. Wöber, J. Zeitlhofer, K. Huber, M. Gröschl, E. Benes, G. Maurer, J. Wojta, M. Gottsauner-Wolf: Can a commercial diagnostic ultrasound device accelerate thrombolysis? – An *in vitro* stroke model. **Stroke 36**: 124-128, 2005
109. W.S. Speidl, A. Zeiner, M. Nikfardjam, A. Geppert, N. Jordanova, A. Niessner, G. Zorn, G. Maurer, W. Schreiber, J. Wojta, K. Huber: An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. **J. Am. Coll. Cardiol. 45**: 30-34, 2005
110. G. Christ, M. Nikfardjam, R. Huber-Beckmann, M. Gottsauner-Wolf, D. Glogar, B.R. Binder, J. Wojta, K. Huber: Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: Dependence on stent implantation and antithrombotic medication. **J. Thromb. Haemost. 3**: 233-239, 2005
111. R. Jarai, N. Jordanova, R. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyongyosi, G. Geyer, J. Wojta, K. Huber: Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. **Europ. Heart J. 26**: 250-256, 2005
112. A. Niessner, S. Graf, M. Nikfardjam, S. Lehr, G. Maurer, J. Wojta, K. Huber: The adaptive immune system and long-term outcome in patients with stable coronary disease: Predictive value of routine laboratory measurements. **Thromb. Haemost. 93**: 257-260, 2005

113. N. Jordanova, M. Gyöngyösi, A. Khorsand, C. Falkensammer, G. Zorn, J. Wojta, A. Anvari, K. Huber: New cut off values of cardiac markers for risk stratification of angina pectoris. **Int. J. Cardiol.** **99**: 429-435, 2005
114. S. Steiner, W.S. Speidl, J. Pleiner, D. Seidinger, C. Kaun, J. Wojta, M. Wolzt, E. Minar, C.W. Kopp: Simvastatin blunts endotoxin-induced tissue factor in vivo. **Circulation** **111**: 1841-1846, 2005
115. G. Rega, C. Kaun, T.W. Weiss, S. Demyanets, G. Zorn, S.P. Kastl, S. Steiner, D. Seidinger, C.W. Kopp, M. Frey, R. Roehle, G. Maurer, K. Huber, J. Wojta*: The inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. **Circulation** **111**: 1938-1945, 2005
116. A. Niessner, R. Marculescu, A. Haschemi, G. Endler, G. Zorn, C.M. Weyand, G. Maurer, C. Mannhalter, J. Wojta, O. Wagner, K. Huber: Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome: A possible implication of fractalkine in inflammatory activation. **Thromb. Haemost.** **93**: 949-954, 2005
117. T.W. Weiss, H. Kvakan, C. Kaun, G. Zorn, W.S. Speidl, S. Pfaffenberger, G. Maurer, K. Huber, J. Wojta*: The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through erk1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: A possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. **J. Mol. Cell. Cardiol.** **39**: 545-551, 2005
118. S. Pfaffenberger, B. Devcic-Kuhar, S.P. Kastl, K. Huber, G. Maurer, J. Wojta, M. Gottsauner-Wolf: Ultrasound thrombolysis. **Thromb. Haemost.** **94**: 26-36, 2005
119. W.S. Speidl, M. Exner, J. Amighi, S.P. Kastl, G. Zorn, G. Maurer, O. Wagner, K. Huber, E. Minar, J. Wojta, M. Schillinger: Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. **Eur. Heart J.** **26**: 2294-2299, 2005
120. T. Gulesserian, C. Wenzel, G. Endler, R. Sunder-Plassmann, C. Marsik, C. Mannhalter, N. Iordanova, M. Gyongyosi, J. Wojta, S. Mustafa, O. Wagner, K. Huber: Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. **Clin. Chem.** **51**: 1661-1665, 2005
121. S. Steiner, A. Niessner, S. Ziegler, B. Richter, D. Seidinger, J. Pleiner, M. Penka, M. Wolzt, K. Huber, J. Wojta, E. Minar, C.W. Kopp: Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. **Atherosclerosis** **181**: 305-310, 2005
122. T. Hoechtl, A. Geppert, M. Nuernberg, G. Unger, W. Speidl, J. Wojta, K. Huber: Direct and indirect antithrombins in acute coronary syndromes. **Wien. Klin. Wochenschr.** **117**: 792-800, 2005

123. R. Jarai, J. Wojta, K. Huber: Circulating B-type natriuretic peptides in patients with acute coronary syndromes: pathophysiological, prognostical and therapeutical considerations. **Thromb. Haemost. 94**: 926-932, 2005
124. A. Niessner, R. Marculescu, H. Kvakan, A. Haschemi, G. Endler, C.M. Weyand, G. Maurer, C. Mannhalter, J. Wojta, O. Wagner, K. Huber: Fractalkine receptor polymorphisms V249I and T280M as genetic risk factors for restenosis. **Thromb. Haemost.94**: 1251-1256, 2005
125. B. Richter, A. Niessner, M. Penka, M. Grdić, S. Steiner, B. Strasser, S. Ziegler, G. Zorn, G. Maurer, V. Simeon-Rudolf, J. Wojta, Kurt Huber: Endurance training reduces circulating asymmetric dimethylarginine (ADMA) and myeloperoxidase (MPO) levels in persons at risk of coronary events. **Thromb. Haemost. 94**: 1306-1311, 2005
126. B. Sturm, D. Stupphann, C. Kaun, S. Boesch, J. Wojta, H. Goldenberg, B. Scheiber-Mojdehkar: Recombinant human erythropoietin: effects on frataxin expression in vitro. **Europ. J. Clin. Invest. 35**: 711-717, 2005
127. S. Demyanets, C. Kaun, G. Maurer, K. Huber, J. Wojta*. Statins modulate expression of components of the plasminogen activator/plasmin system in human cardiac myocytes in vitro. **J. Thromb. Haemost. 4**: 476-479, 2006
128. S. Demyanets, S. Pfaffenberger, C. Kaun, G. Rega, W.S. Speidl, S.P. Kastl, T.W. Weiss, P.J. Hohensinner, W. Dietrich, W. Tschugguel, V.N. Bochkov, E.M. Awad, G. Maurer, K. Huber, J. Wojta*: The estrogen metabolite 17 β -dihydroequilenin counteracts interleukin-1 α induced expression of inflammatory mediators in human endothelial cells *in vitro* via NF- κ B pathway. **Thromb. Haemost. 95**: 107-116, 2006
129. A. Niessner, B. Richter, M. Penka, S. Steiner, B. Strasser, S. Ziegler, E. Heeb-Elze, G. Zorn, A. Leitner-Heinschink, C. Niessner, J. Wojta, K. Huber: Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? **Atherosclerosis 186**: 160-165, 2006
130. A. Niessner, S. Steiner, W.S. Speidl, J. Pleiner, D. Seidinger, G. Maurer, J.J. Goronzy, C.M. Weyand, C.W. Kopp, K. Huber, M. Wolzt, J. Wojta: Simvastatin suppresses endotoxin-induced upregulation of toll-like receptor 4 and 2 *in vivo*. **Atherosclerosis 189**: 408-413, 2006
131. S. Demyanets, C. Kaun, S. Pfaffenberger, P.J. Hohensinner, G. Rega, J. Pammer, G. Maurer, K. Huber, J. Wojta*: Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes *in vitro*. **Biochem. Pharmacol. 71**: 1324-1330, 2006
132. T.W. Weiss, H. Kvakan, C. Kaun, M. Prager, W.S. Speidl, G. Zorn, S. Pfaffenberger, I. Huk, G. Maurer, K. Huber, J. Wojta*: No evidence for a direct role of helicobacter pylori and mycoplasma pneumoniae in carotid artery atherosclerosis based on their respective presence in the atherosclerotic plaque, in healthy vessels and in circulating leukocytes from the same individuals. **J. Clin. Pathol. 59**: 1186-1190, 2006

133. P.J. Hohensinner, C. Kaun, K. Rychli, E. Ben-Tal Cohen, S.P. Kastl, S. Demyanets, S. Pfaffenberger, W.S. Speidl, G. Rega, R. Ullrich, G. Maurer, K. Huber, J. Wojta*: Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. **FEBS Lett.** **580**: 3532-3538, 2006
134. S.P. Kastl, W.S. Speidl, C. Kaun, G. Rega, A. Assadian, T.W. Weiss, P. Valent, G.W. Hagmueller, G. Maurer, K. Huber, J. Wojta*: The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF- κ B activation. **J. Thromb. Haemost.** **4**: 1790-1797, 2006
135. M. Gyöngyösi, C. Strehlow, W. Sperker, A. Hevesi, R. Garamvölgyi, Z. Petrasi, N. Pavo, P. Ferdinandy, C. Csonka, T. Csont, C. Sylven, P.J. Declerck, I. Pavo, J. Wojta, D. Glogar, K. Huber. Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombotic response of drug-eluting or bare stent implantation within the first 24 hours. **Thromb. Haemost.** **96**: 202-209, 2006
136. V.N. Bochkov, M. Philippova, O. Oskolkova, A. Kadl, A. Furnkranz, E. Karabeg, T. Afonyushkin, F. Gruber, J. Breuss, A. Minchenko, D. Mechtcheriakova, P. Hohensinner, K. Rychli, J. Wojta, T. Resink, P. Erne, B.R. Binder, N. Leitinger: Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. **Circ. Res.** **99**: 900-908, 2006
137. E. Ben-Tal Cohen, P.J. Hohensinner, C. Kaun, G. Maurer, K. Huber, J. Wojta*: Statins decrease TNF- α induced osteoprotegerin production by endothelial cells and smooth muscle cells *in vitro*. **Biochem. Pharmacol.** **73**: 77-83, 2007
138. W.S. Speidl, M. Nikfardjam, A. Niessner, A. Zeiner, N. Jordanova, G. Zorn, G. Maurer, W. Schreiber, J. Wojta, K. Huber: Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity inpatients after ST-elevation myocardial infarction. **Thromb. Res.** **119**: 331-336, 2007
139. W.S. Speidl, M. Exner, J. Amighi, W. Mlekusch, S. Sabeti, S.P. Kastl, G. Zorn, G. Maurer, O. Wagner, K. Huber, E. Minar, J. Wojta, M. Schillinger: Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty. **J. Endovasc. Ther.** **14**: 62-69, 2007
140. W.S. Speidl, M. Nikfardjam, A. Niessner, N. Jordanova, G. Zorn, G. Maurer, W. Schreiber, J. Wojta, K. Huber: Premature compared to late onset of coronary artery disease: Young patients show a severe defect in fibrinolytic response to venous occlusion. **Blood Coag. Fibrinol.** **18**: 165-171, 2007
141. J. Siller-Matula, K. Schror, J. Wojta, K. Huber: Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. **Thromb. Haemost.** **97**: 385-389, 2007
142. T. Höchtel, L. Pachinger, G. Unger, A. Geppert, J. Wojta, J. Harenberg, K. Huber: Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports. **J. Thromb. Thrombolysis.** **24**: 59-64, 2007

143. M. Mildner, V. Mlitz, F. Gruber, J. Wojta, E. Tschachler: Hepatocyte growth factor establishes autocrine and paracrine feedback loops for the protection of skin cells after UV-irradiation. **J. Invest. Dermatol.** **127**: 2637-2644, 2007
144. G. Rega, C. Kaun, S. Demyanets, S. Pfaffenberger, K. Rychli, P.J. Hohensinner, S.P. Kastl, W.S. Speidl, T. W. Weiss, J.M. Breuss, A. Furnkranz, P. Uhrin, J. Zaujec, V. Zilberfarb, M. Frey, R. Roehle, G. Maurer, K. Huber, J. Wojta*: Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin M in human adipose tissue *in vitro* and in murine adipose tissue *in vivo*. **Arterioscler. Thromb. Vasc. Biol.** **27**: 1587-1595, 2007
145. S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V.N. Bochkov, G. Maurer, K. Huber, J. Wojta*: The inflammatory cytokine oncostatin M induces plasminogen activator inhibitor-1 in human vascular smooth muscle cells in vitro via PI3 kinase and ERK 1/2 dependent pathways. **Amer. J. Physiol. Heart Circ. Physiol.** **293**: H1962-H1968, 2007
146. P.J. Hohensinner, C. Kaun, K. Rychli, A. Niessner, S. Pfaffenberger, G. Rega, R. de Martin, G. Maurer, R. Ullrich, K. Huber, J. Wojta*: Macrophage colony stimulating factor expression in human cardiac cells is upregulated by tumor necrosis factor-alpha via NF-kappaB dependent mechanism. **J. Thromb. Haemost.** **5**: 2520-2528, 2007
147. R. Jarai, N. Iordanova, R. Jarai, F. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyöngyösi, G. Geyer, J. Wojta, K. Huber: Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. **Wien. Klin. Wochenschr.** **119**: 626-632, 2007
148. K.M. Katsaros, W.S. Speidl, S.P. Kastl, G. Zorn, K. Huber, G. Maurer, D. Glogar, J. Wojta, G. Christ: Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. **J. Thromb. Haemost.** **6**: 508-513, 2008
149. S.P. Kastl, W.S. Speidl, C. Kaun, K.M. Katsaros, G. Rega, T. Afonyushkin, V.N. Bochkov, P. Valent, A. Assadian, G.W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, G. Maurer, K. Huber, J. Wojta*: In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. **Arterioscler. Thromb. Vasc. Biol.** **28**: 498-503, 2008
150. J. Kern, M. Bauer, K. Rychli, J. Wojta, A. Ritsch, G. Gastl, E. Gunsilius, G. Untergasser: Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation. **Arterioscler. Thromb. Vasc. Biol.** **28**: 478-84, 2008
151. P. Wexberg, N. Iordanova, B. Syeda, B. Meyer, S. Charwat, G. Zorn, D. Scheinig, J. Wojta, K. Huber, D. Glogar, M. Gyöngyösi: Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation. **Thromb. Haemost.** **99**: 739-748, 2008

152. K.M. Katsaros, S.P. Kastl, K. Huber, G. Zorn, G. Maurer, D. Glogar, J. Wojta, G. Christ, W.S. Speidl: Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation. **Thromb. Res.** **123**: 79-84, 2008
153. M. Gyöngyösi, J. Blanco, T. Marian, L. Tron, Ö. Petnehaz, Z. Petrasi, R. Hemetsberger, J. Rodriguez, G. Font, I. Pavo jr, I. Kertesz, L. Balkay, N. Pavo, A. Posa, M. Emri, L. Galuska, D.L. Kraitchman, J. Wojta, K. Huber, D. Glogar. Serial non-invasive in vivo positron emission tomographic (PET) tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. **Circ. Cardiovasc. Imaging** **1**: 94-103, 2008
154. P. J. Hohensinner, C. Kaun, K. Rychli, A. Niessner, S. Pfaffenberger, G. Rega, A. Furnkranz, P. Uhrin, J. Zaujec, T. Afonyushkin, V.N. Bochkov, G. Maurer, K. Huber, J. Wojta*. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. **FASEB J.** **23**: 774-782, 2009
155. A. Niessner, P.J. Hohensinner, K. Rychli, S. Neuhold, G. Zorn, B. Richter, M. Hülsmann, R. Berger, D. Mörtl, K. Huber, J. Wojta*, R. Pacher. Prognostic value of apoptosis markers in advanced heart failure patients. **Eur. Heart J.** **30**: 789-796, 2009
156. R. Jarai, C. Kaun, T.W. Weiss, W.S. Speidl, K. Rychli, G. Maurer, K. Huber, J. Wojta*. Human cardiac fibroblasts express B-type natriuretic peptide. Fluvastatin ameliorates its upregulation by interleukin-1 α , tumor necrosis factor- α and transforming growth factor- β . **J. Cell. Mol. Med.** **13**: 4415-4421, 2009
157. U. Hanusch-Enserer, G. Zorn, J. Wojta, C.W. Kopp, R. Prager, W. Koenig, M. Roden, K. Huber, M. Schillinger. Non-conventional markers of atherosclerosis before and after gastric banding surgery. **Eur. Heart J.** **30**: 1516-1524, 2009
158. S.P. Kastl, W.S. Speidl, K.M. Katsaros, C. Kaun, G. Rega, A. Assadian, G.W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, G. Maurer, K. Huber, J. Wojta*. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages. A link between coagulation and inflammation. **Blood** **114**: 2812-2818, 2009
159. K. Rychli, K. Huber, J. Wojta*. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. **Expert Opin. Ther. Targets** **13**: 1295-1302, 2009
160. F. Wiesbauer, H. Blessberger, G. Goliash, E. Holy, S. Pfaffenberger, I. Tentzeris, G. Maurer, K. Huber, F. Abdolvahab, G. Sodeck, M. Exner, J. Wojta, M. Schillinger. Elevated risk of myocardial infarction in very young immigrants from former yugoslavia. **Eur. J. Epidemiol.** **24**: 691-696, 2009
161. K. Rychli, C. Kaun, P.J. Hohensinner, A. Dorfner, S. Pfaffenberger, A. Niessner, M. Bauer, W. Dietl, B.P. Podesser, G. Maurer, K. Huber, J. Wojta*. The antiangiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts. **J. Cell. Mol. Med.** **14**: 198-205, 2010

162. W.S. Speidl, K.M. Katsaros, S.P. Kastl, G. Zorn, K. Huber, G. Maurer, D. Glogar, J. Wojta, G. Christ. Coronary late lumen loss of drug-eluting stents is associated with increased serum levels of the complement components C3a and C5a. **Atherosclerosis** **208**: 285-289, 2010
163. K.M. Katsaros, S.P. Kastl, G. Zorn, G. Maurer, J. Wojta, K. Huber, G. Christ, W.S. Speidl. Increased restenosis rate after implantation of drug eluting stents in patients with elevated serum activity of MMP-2 and MMP-9. **J. Am. Coll. Cardiol. Intervent.** **3**: 90-97, 2010
164. P.J. Hohensinner, K. Rychli, G. Zorn, M. Huelsmann, R. Berger, D. Mörtl, B. Richter, K. Huber, J. Wojta, R. Pacher, A. Niessner. Macrophage-modulating cytokines predict adverse outcome in heart failure. **Thromb. Haemost.** **103**: 435-441, 2010
165. K. Rychli, C. Kaun, P.J. Hohensinner, G. Rega, S. Pfaffenberger, E. Vyskocil, J.M. Breuss, A. Furnkranz, P. Uhrin, J. Zaujec, A. Niessner, G. Maurer, K. Huber, J. Wojta*. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. **J. Thromb. Haemost.** **8**: 596-604, 2010
166. S. Farhan, T. Höchtel, A. Kautzky-Willer, J. Wojta, H. Huber. Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. **Wien. Med. Wochenschr.** **160**: 30-38, 2010.
167. M. Gyöngyösi, A. Posa, N. Pavo, R. Hemetsberger, H. Kvakan, S. Steiner-Böker, Z. Petrösi, F. Manczur, I.J. Pavo, I.F. Edes, J. Wojta, D. Glogar, K. Huber. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. **Thromb. Haemost.** **104**: 376-384, 2010
168. K. Rychli, A. Niessner, P.J. Hohensinner, K. Mahdy Ali, C. Kaun, S. Neuhold, G. Zorn, B. Richter, M. Hülsmann, R. Berger, D. Mörtl, K. Huber, G. Maurer, R. Pacher, J. Wojta. Prognostic value of pigment epithelium-derived factor in advanced heart failure patients. **Chest** **138**: 656-664, 2010
169. B. Richter, M. Gwechenberger, A. Socas, G. Zorn, S. Albinni, M. Marx, F. Wolf, J. Bergler-Klein, C. Loewe, C. Bieglmayer, T. Binder, J. Wojta, H.D. Gössinger. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. **Int. J. Cardiol.** **152**: 231-236, 2010
170. B. Richter, K. Rychli, P.J. Hohensinner, R. Berger, D. Mörtl, S. Neuhold, G. Zorn, K. Huber, G. Maurer, J. Wojta, R. Pacher, M. Hülsmann, A. Niessner. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. **Atherosclerosis** **213**: 545-548, 2010
171. S. Farhan, T. Höchtel, J. Wojta, K. Huber. Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease. **Minerva Med.** **101**: 239-253, 2010
172. O.V. Oskolkova, T. Afonyushkin, B. Preinerstorfer, W. Bicker, E. von Schlieffen, E. Hainzl, S. Demyanets, G. Schabbauer, W. Lindner, A.D. Tselepis, J. Wojta, B.R. Binder,

- V.N. Bochkov. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. **J. Immunol.** **185:** 7706-7712, 2010
173. I. Tentzeris, R. Jarai, S. Farhan, I. Brozovic, P. Smetana, A. Geppert, J. Wojta, J. Siller-Matula, K. Huber. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. **Thromb. Haemost.** **104:** 1211-1218, 2010
174. T.W. Weiss, S. Schumacher, C. Kaun, K.M. Katsaros, M. Troseid, K. Huber, G. Maurer, J. Wojta. Association between smoking and presence of mycoplasma pneumoniae in circulation leukocytes. **Swiss Med. Weekly**, in press 2010
175. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, S.D. Anker, M. Avkiran, E. de Azambuja, J.L. Balligand, D.L. Brutsaert, G. Condorelli, A. Hansen, S. Heymans, J.A. Hill, E. Hirsch, D. Hilfiker-Kleiner, S. Janssens, S. de Jong, G. Neubauer, B. Pieske, P. Ponikowski, M. Pirmohamed, M. Rauchhaus, D. Sawyer, P.H. Sugden, J. Wojta, F. Zannad, A.M. Shah. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. **Europ. J. Heart Failure** **13:** 1–10, 2011
176. T. Höchtl, S. Farhan, J. Wojta, K. Huber. New anticoagulant agents in acute coronary syndromes. **Heart** **97:** 244-252, 2011
177. W.S. Speidl, S.P. Kastl, R. Hutter, K.M. Katsaros, C. Kaun, G. Bauriedel, G. Maurer, K. Huber, J.J. Badimon, J. Wojta*. The complement component C5a is present in human coronary lesions *in vivo* and induces the expression of MMP-1 and MMP-9 in human macrophages *in vitro*. **FASEB J.** **25:** 35-44, 2011
178. S. Demyanets, C. Kaun, K. Rychli, S. Pfaffenberger, S.P. Kastl, P.J. Hohensinner, G. Rega, K.M. Katsaros, T. Afonyushkin, V.N. Bochkov, M. Paireder, I. Huk, G. Maurer, K. Huber, J. Wojta*. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon- γ . **Basic Res. Cardiol.** **106:** 217-231, 2011
179. W.S. Speidl, S.P. Kastl, K. Huber, J. Wojta*. Complement in atherosclerosis – friend or foe? **J. Thromb. Haemost.** **9:** 428-440, 2011
180. G. Goliash, H. Blessberger, D. Azar, G. Heinze, J. Wojta, C. Bieglmayer, O. Wagner, M. Schillinger, K. Huber, G. Maurer, M. Haas, F. Wiesbauer. Markers of Bone Metabolism in premature myocardial infarction (≤ 40 years of age). **Bone** **48:** 622-626, 2011
181. I. Tentzeris, R. Jarai, S. Farhan, J. Wojta, M. Schillinger, A. Geppert, M. Nürnberg, G. Unger, K. Huber. Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. **Clin. Res. Cardiol.** **100:** 191-200, 2011
182. G. Goliash, F. Wiesbauer, A. Grafl, E. Ponweiser, H. Blessberger, I. Tentzeris, J. Wojta, M. Schillinger, K. Huber, G. Maurer, C. Mannhalter, R. Sunder-Plaßmann. The

- effect of P22PHOX polymorphisms on premature coronary artery disease (≤ 40 years of age). **Thromb. Haemost.** **105**: 529-534, 2011
183. M.K. Freynhofer, V. Bruno, R. Jarai, S. Gruber, T. Höchtl, I. Brozovic, S. Farhan, J. Wojta, K. Huber. Levels of VWF and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation. **Thromb. Haemost.** **105**: 435-443, 2011
 184. K.M. Katsaros, F. Wiesbauer, W.S. Speidl, S.P. Kastl, K. Huber, G. Zorn, A. Niessner, D. Glogar, G. Maurer, J. Wojta*. High soluble Fas and soluble Fas ligand serum levels before stent implantation are protective against restenosis. **Thromb. Haemost.** **105**: 883-891, 2011
 185. M.K. Freynhofer, R. Jarai, T. Höchtl, V. Bruno, B. Vogel, K. Aydinkoc, M. Nürnberg, J. Wojta, K. Huber. Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion. **Int. J. Cardiol.** **149**: 257-259, 2011
 186. P.J. Hohensinner, A. Niessner, K. Huber, C.M. Weynad, J. Wojta. Inflammation and cardiac outcome. **Curr. Opin. Infect. Dis.** **24**: 259-264, 2011
 187. K. Rychli, B. Richter, P.J. Hohensinner, K. Mahdy-Ali, S. Neuhold, G. Zorn, R. Berger, D. Mörtl, K. Huber, R. Pacher, J. Wojta, A. Niessner, M. Hülsmann. Hepatocyte growth factor is a strong predictor of mortality in advanced heart failure patients. **Heart** **97**: 1158-1163, 2011
 188. I. Tentzeris, J. Siller-Matula, S. Farhan, R. Jarai, J. Wojta, K. Huber. Platelet function variability and non-genetic causes. **Thromb. Haemost.** **105 Suppl.**: S60-S66, 2011
 189. I. Tentzeris, R. Jarai, S. Farhan, T. Perkmann, M.A. Schwarz, G. Jakl, J. Wojta, K. Huber. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. **Eur. J. Heart Fail.** **13**: 726-733, 2011
 190. S. Demyanets, K. Huber, J. Wojta*. Inflammation and the cardiovascular system. **Europ. Surg.****43**: 78-89 2011
 191. M.K. Freynhofer, I. Brozovic, V. Bruno, S. Farhan, B. Vogel, G. Jakl, M. Willheim, W. Hübl, J. Wojta, K. Huber. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. **Thromb. Haemost.****106**: 230-239, 2011
 192. S. Demyanets, V. Konya, S.P. Kastl, C. Kaun, S. Rauscher, A. Niessner, R. Pentz, S. Pfaffenberger, K. Rychli, C.E. Lemberger, R. de Martin, A. Heinemann, I. Huk, M. Gröger, G. Maurer, K. Huber, J. Wojta*. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. **Arterioscler. Thromb. Vasc. Biol.** **31**: 2080-2089, 2011
 193. M. Hoke, M. Schillinger, G. Zorn, A. Wonnerth, J. Amighi, W. Mlekusch, G. Maurer, R. Koppensteiner, E. Minar, J. Wojta, A. Niessner. The prognostic impact of sFas on mortality in patients with carotid atherosclerosis. **Stroke** **42**: 2465-2470, 2011

194. T.W. Weiss, H. Arnesen, M. Troseid, C. Kaun, E.M. Hjerkin, K. Huber, J. Wojta, I. Seljeflot. Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose. **Wien. Klin. Wochenschr.** **123**: 650-654, 2011
195. A. Schwarzmaier-D'Assie, N. Nyolczas, R. Hemetsberger, C. Strehblow, Johannes Matiasek, S. Farhan, Z. Petrasi, K. Huber, J. Wojta, D. Glogar, C. Plass, M. Gyöngyösi, R. Karnik. Comparison of short- and long-term results of drug-eluting vs. bare metal stenting in the porcine internal carotid artery. **J. Endovasc. Ther.** **18**: 547-558, 2011
196. T.W. Weiss, R. Simak, C. Kaun, G. Rega, H. Pflüger, G. Maurer, K. Huber, J. Wojta. Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. **Anticancer Res.** **31**: 3273-3278, 2011
197. B. Richter, M. Gwechenberger, A. Socas, G. Zorn, S. Albinni, M. Marx, F. Wolf, J. Bergler-Klein, C. Loewe, C. Bieglmayer, T. Binder, J. Wojta, H.D. Gössinger. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. **Int. J. Cardiol.** **152**: 231-236, 2011
198. S. Farhan, R. Jarai, I. Tentzeris, M.K. Freynhofer, I. Brozovic, B. Vogel, A. Kautzky-Willer, T. Wascher, J. Wojta, K. Huber. Admission proinsulin is associated with mortality in patients with admission hyperglycemia during acute coronary syndrome: results from a pilot observational study. **Clin. Chem.** **57**: 1456-60, 2011
199. B. Richter, M. Gwechenberger, A. Socas, G. Zorn, S. Albinni, M. Marx, J. Bergler-Klein, T. Binder, J. Wojta, H.D. Gössinger. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. **Clin. Res. Cardiol.** **101**: 217-225, 2012
200. S. Demyanets, K. Huber, J. Wojta*. Vascular effects of glycoprotein130 ligands - Part I: Pathophysiological role. **Vascul. Pharmacol.** **56**: 34-46, 2012
201. S. Demyanets, K. Huber, J. Wojta*. Vascular effects of glycoprotein130 ligands - Part II: Biomarkers and therapeutic targets. **Vascul. Pharmacol.** **57**: 29-40, 2012
202. G. Goliash, S. Oravec, H. Blessberger, E. Dostal, M. Hoke, J. Wojta, M. Schillinger, K. Huber, G. Maurer, F. Wiesbauer. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age). **Eur. J. Clin. Invest.** **42**: 631-636, 2012
203. M.K. Freynhofer, V. Bruno, M. Willheim, W. Hübl, J. Wojta, K. Huber. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter? **Thromb Haemost.** **107**: 538-544, 2012
204. S. Farhan, R. Jarai, I. Tentzeris, A. Kautzky-Willer, E. Samaha, P. Smetana, G. Jakl-Kotauschek, J. Wojta, K. Huber. Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. **Clin. Res. Cardiol.** **101**: 625-630, 2012

205. G. Goliash, F. Wiesbauer, S.P. Kastl, K.M. Katsaros, H. Blessberger, G. Maurer, M. Schillinger, K. Huber, J. Wojta, W.S. Speidl. Premature myocardial infarction is associated with low serum levels of Wnt-1. **Atherosclerosis** **222**: 251-256, 2012
206. K.R. Heberlein, J. Han, A.C. Straub, A.K. Best, C. Kaun, J. Wojta, B.E. Isakson. A novel mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 accumulation at the myoendothelial junction. **Arterioscler. Thromb. Vasc. Biol.** **32**: 1271-1279, 2012
207. A. Piechota-Polanczyk, A. Goraca, S. Demyanets, M. Mittlboeck, C. Domenig, C. Neumayer, J. Wojta, J. Nanobachvili, I. Huk, M. Klingler. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF- κ B. **Eur. J. Vasc. Endovasc. Surg.** **44**: 133-137, 2012
208. M.K. Freynhofer, V. Bruno, J. Wojta, K. Huber. The role of platelets in atherothrombotic events. **Curr. Pharm. Des.** **18**: 5197-5214, 2012
209. K. Mahdy Ali, A. Wonnerth, K. Huber, J. Wojta*. Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future opportunities. **Br. J. Pharmacol.** **167**: 1177-1194, 2012
210. S. Demyanets, J. Wojta*. Sex differences in effects and use of anti-inflammatory drugs. **Handb. Exp. Pharmacol.** **214**: 443-72, 2012
211. M.K. Freynhofer, M. Tajsic, J. Wojta, K. Huber. Biomarkers in acute coronary artery disease. **Wien. Med. Wochenschr.** **162**: 489-498, 2012
212. B. Richter, L. Koller, P.J. Hohensinner, K. Rychli, G. Zorn, G. Goliash, R. Berger, D. Mörtl, G. Maurer, K. Huber, R. Pacher, J. Wojta, M. Hülsmann, A. Niessner. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. **Thromb. Haemost.** **108**: 1220-1227, 2012
213. E. Vyskocil, S. Pfaffenberger, C. Kollmann, A. Gleiss, G. Nawratil, S. Kastl, E. Unger, K. Aumayr, O. Schuhfried, K. Huber, J. Wojta, M. Gottsauner-Wolf. Thermal effects of diagnostic ultrasound in an anthropomorphic skull model. **Ultraschall Med.** **37**: E313-E320, 2012
214. M. Zeyda, B. Wernly, S. Demyanets, C. Kaun, M. Hämmerle, B. Hantusch, M. Schranz, A. Neuhofer, B.K. Itariu, M. Keck, G. Prager, J. Wojta, T.M. Stulnig. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. **Int. J. Obes.** **37**: 658-665, 2013
215. J. Wojta. Factor XIII and alternatively activated macrophages – new targets in aortic valve stenosis. **Thromb. Haemost.** **108**: 1023, 2012
216. M.K. Freynhofer, S.C. Gruber, V. Bruno, T. Höchtel, S. Farhan, V. Zaller, J. Wojta, K. Huber. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. **Int. J. Cardiol.** **168**: 317-325, 2013

217. B. Richter, L. Koller, P.J.Hohensinner, G. Zorn, M. Brekalo, R. Berger, D. Mörtl, G. Maurer, R. Pacher, K. Huber, J. Wojta, M. Hülsmann, A. Niessner. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. **Int J Cardiol. 168**: 1251-1257, 2013
218. S. Pfaffenberger, E. Vyskocil, C. Kollmann, E. Unger, C. Kaun, S. Kastl, C. Woeber, G. Nawratil, K. Huber, G. Maurer, M. Gottsauner-Wolf§, J. Wojta§. Transtemporal ultrasound application potentially elevates brain temperature: Results of an anthropomorphic skull model. **Ultraschall Med. 34**: 51-57, 2013
219. M.K. Freynhofer, D.F. Draxler, S.C. Gruber, V. Bruno, T. Höchtel, B. Fellner, G. Jakl-Kotauschek, J. Wojta, I. Pabinger-Fasching, K. Huber, C. Ay. Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all cause death in patients with atrial fibrillation. **J. Thromb. Haemost. 11**: 1069-1077, 2013
220. A. Piechota-Polanczyk, S. Demyanets, O. Nykonenko, I. Huk, M. Mittlboeck, C.M. Domenig, C. Neumayer, J. Wojta, J. Nanobachvili, M. Klingler. Decreased tissue levels of cyclophilin A, a cyclosporine A target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. **Eur. J. Vasc. Endovasc. Surg. 45**: 682-688, 2013
221. S. Demyanets, C. Kaun, R. Pentz, K.A. Krychtiuk, S. Rauscher, S. Pfaffenberger, A. Zuckermann, A. Aliabadi, M. Gröger, G. Maurer, K. Huber, J. Wojta. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. **J. Mol. Cell. Cardiol. 60**: 16-26, 2013
222. N. Duschek, S. Ghai, F. Sejkic, J. Falkensammer, E. Skrinjar, K. Huber, J. Wojta, T. Waldhör, W. Hübl, A. Assadian. Homocysteine improves risk stratification in patients undergoing endarterectomy for asymptomatic internal carotid artery stenosis. **Stroke 44**: 2311-2314, 2013
223. E. Awad, S. Khan, B. Sokolikova, P. Brunner, D. Olcaydu, J. Wojta, J. Breuss, P. Uhrin. Cold induces ROS-production and activation of the NF-kappa B response in endothelial cells and inflammation in vivo. **J. Thromb. Haemost. 11**: 1716-1726, 2013
224. G. Rega-Kaun, C. Kaun, J. Wojta*. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. **Thromb. Haemost. 110**: 641-650, 2013
225. M.C. Alessi, J. Wojta*. Obesity and vascular disease: from bench to bedside. **Thromb. Haemost. 110**: 632-633, 2013
226. L. Koller, B. Richter, G. Goliash, S. Blum, M. Korpak G. Zorn, M. Brekalo, G. Maurer, J. Wojta, R. Pacher, M. Hülsmann, A. Niessner. CD4(+)CD28(null) cells are an independent predictor of mortality in patients with heart failure. **Atherosclerosis 230**: 414-416, 2013.
227. L. Koller, S. Blum, M. Korpak, B. Richter, G. Goliash, G. Zorn, M. Brekalo, G. Maurer, J. Wojta, R. Pacher, M. Hülsmann, A. Niessner. Predictive power of the fractalkine

- receptor CX3CR1 on CD4 T cells in patients with chronic heart failure. **Int. J. Cardiol.** **171**: 96-97 2014
228. M.K. Freynhofer, V. Bruno, I. Brozovic, R. Jarai, B. Vogel, S. Farhan, W. Hübl, M. Willheim, J. Wojta, K. Huber. Variability of on-treatment platelet reactivity in patients on clopidogrel. **Platelets** **25**: 328-336, 2014
229. K.A. Krychtiuk, S.P. Kastl, W.S. Speidl, J. Wojta. Inflammation and coagulation in atherosclerosis. **Haemostas.** **33**: 269-82, 2013
230. K.M. Katsaros, S.P. Kastl, K.A. Krychtiuk, R. Hutter, G. Zorn, G. Maurer, K. Huber, J. Wojta, G. Christ, W.S. Speidl. An increase in VEGF plasma levels is associated with restenosis of drug-eluting stents. **Eurointervention** **10**: 224-230, 2014
231. M. Rohla, M.K. Freynhofer, I. Tentzeris, S. Farhan, J. Wojta, K. Huber, T.W. Weiss. Plasma osmolality predicts clinical outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention. **Eur. Heart J. Acute Cardiovasc. Care** **3**: 84-92, 2014
232. I. Tentzeris, M. Rohla, R. Jarai, S. Farhan, M.K. Freynhofer, G. Unger, M. Nürnberg, A. Geppert, E. Wessely, J. Wojta, K. Huber. Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes. **Am. J. Cardiol.** **113**: 1099-1104, 2014
233. A. Wonnerth, K.M. Katsaros, K.A. Krychtiuk, W.S. Speidl, C. Kaun, K. Thaler, K. Huber, J. Wojta, G. Maurer, I. Seljeflot, H. Arnesen, T.W. Weiss. Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels. **Metabolism** **63**: 647-653, 2014
234. K.A. Krychtiuk, M. Nürnberg, R. Volker, L. Pachinger, R. Jarai, M.K. Freynhofer, J. Wojta, K. Huber, T.W. Weiss. Effects of AV-delay optimization on hemodynamic parameters in patients with VDD pacemakers. **Wien. Klin. Wochenschr.** **126**: 270-277, 2014
235. S. Stojkovic, C. Kaun, M. Heinz, K.A. Krychtiuk, S. Rauscher, C.E. Lemberger, R. de Martin, M. Gröger, P. Petzelbauer, I. Huk, K. Huber, J. Wojta*, S. Demyanets. Interleukin-33 induces urokinase in human endothelial cells-possible impact on angiogenesis. **J. Thromb. Haemost.** **12**: 948-57, 2014
236. S. Demyanets, I. Tentzeris, R. Jarai, K.M. Katsaros, S. Farhan, A. Wonnerth, T.W. Weiss, J. Wojta, W.S. Speidl, K. Huber. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. **Cytokine**: 65-70, 2014
237. S. Demyanets, W.S. Speidl, I. Tentzeris, R. Jarai, K.M. Katsaros, S. Farhan, K.A. Krychtiuk, A. Wonnerth, T.W. Weiss, K. Huber, J. Wojta. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. **PLoS One** **9**: e95055, 2014

238. K.A. Krychtiuk, S.P. Kastl, S. Pfaffenberger, T. Pongratz, S.L. Hofbauer, A. Wonnerth, K.M. Katsaros, G. Goliash, L. Gaspar, K. Huber, G. Maurer, E. Dostal, S. Oravec, J. Wojta*, W.S. Speidl. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. **Atherosclerosis** **237**: 589-596, 2014
239. K.A. Krychtiuk, L. Watzke, C. Kaun, E. Buchberger, R. Hofer-Warbinek, S. Demyanets, J. Pisoni, S.P. Kastl, S. Rauscher, M. Gröger, A. Aliabadi, A. Zuckermann, G. Maurer, R. de Martin, K. Huber, J. Wojta*, W.S. Speidl. Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. **Thromb. Haemost.** **113**: 350-362, 2014
240. E. Kozarov, K. Huber, J. Wojta. Infection-associated biomarkers of inflammation in atherosclerosis. **Curr. Pharm. Des.** **21**: 1776-1782, 2014
241. S. Stojkovic, R. Ristl, F.T. Moser, M. Wolzt, J. Wojta, H. Schmidinger, T. Pezawas. T-wave variability for the prediction of fast ventricular arrhythmias. **Circ. J.** **79**: 318-324, 2015
242. K.A. Krychtiuk, S.P. Kastl, S. Pfaffenberger, M. Lenz, S.L. Hofbauer, A. Wonnerth, L. Koller, K.M. Katsaros, T. Pongratz, G. Goliash, A. Niessner, L. Gaspar, K. Huber, G. Maurer, E. Dostal, J. Wojta*, S. Oravec, W.S. Speidl. Association of small dense LDL is and circulating monocyte subsets in stable coronary artery disease. **PLoS One** **10**: e0123367, 2015
243. M. Rohla, C.K. Vennekate, I. Tentzeris, M.K. Freynhofer, S. Farhan, F. Egger, T.W. Weiss, J. Wojta, C.B. Granger, K. Huber. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. **Int. J. Cardiol.** **184**: 108-114, 2015
244. A. Piechota-Polanczyk, S. Demyanets, M. Mittlboeck, M. Hofmann, C.M. Domenig, C. Neumayer, J. Wojta, M. Klinger, J. Nanobachvili, I. Huk. The influence of simvastatin on NGAL, matrix metalloproteinases and their tissue inhibitors in human intraluminal thrombus and abdominal aortic aneurysm tissue. **Eur. J. Vasc. Endovasc. Surg.** **49**: 549-55, 2015
245. K. Distelmaier, F. Wiesbauer, H. Blessberger, S. Oravec, L. Schrutka, C. Binder, E. Dostal, M. Schillinger, J. Wojta, I.M. Lang, G. Maurer, K. Huber, G. Goliash. Impaired antioxidant HDL function is associated with premature myocardial infarction. **Eur. J. Clin. Invest.** **45**: 731-718, 2015
246. P. Sulzgruber, L. Koller, T. Reiberger, F. El-Hamid, S. Forster, D.J. Rothgerber, G. Goliash, J. Wojta, A. Niessner. Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome. **PLoS One** **10**: 0123948, 2015
247. K.A. Krychtiuk, S. Ruhittel, P.J. Hohensinner, L. Koller, C. Kaun, M. Lenz, B. Bauer, L. Wutzlhofer, D.F. Draxler, G. Maurer, K. Huber, J. Wojta, G. Heinz, A. Niessner, W.S. Speidl. Mitochondrial DNA and toll-like receptor 9 are associated with mortality in critically ill patients. **Crit. Care Med.** **43**: 2633-2641, 2015

248. K.A. Krychtiuk, S.P. Kastl, Hofbauer S.L., A. Wonnerth, G. Goliash, M. Ozsva-Kozma, K.M. Katsaros, G. Maurer, E. Dostal, C.J. Binder, S. Pfaffenberger, S. Oravec, J. Wojta, W.S. Speidl. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). **J. Clin. Lipidol.** **9**: 533-541, 2015
249. L. Koller, D.J. Rothgerber, P. Sulzgruber, F. El-Hamid, S. Förster, J. Wojta, G. Goliash, G. Maurer, A. Niessner. History of previous bleeding and C-reactive protein improve assessment of bleeding risk in elderly patients (≥ 80 years) with myocardial infarction. **Thromb. Haemost.** **114**: 1085-1091, 2015
250. M.K. Freynhofer, S.C. Gruber, E.L. Grove, T.W. Weiss, J. Wojta, K. Huber. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. **Thromb. Haemost.** **114**: 459-468, 2015
251. J. Wu, J. Stefaniak, C. Hafner, J.P. Schramel, C. Kaun, J. Wojta, R. Ullrich, V.E. Tretter, K. Markstaller, K.U. Klein. Intermittent hypoxia causes inflammation and injury to human adult cardiac myocytes. **Anesth. Analg.** 2015 in press
252. J. Wu, C. Hafner, J.P. Schramel, C. Kaun, K.A. Krychtiuk, J. Wojta, S. Boehme, R. Ullrich, E.V. Tretter, K. Markstaller, K.U. Klein. Cyclic and constant hyperoxia cause inflammation, apoptosis and cell death in human umbilical vein endothelial cells. **Acta Anaesthesiol. Scand.** 2015 in press
253. J. Wojta. Platelet-derived microparticles in patients with high cardiovascular risk and subclinical atherosclerosis. **Thromb. Haemost.** **114**: 1099, 2015
254. K.M. Katsaros, W.S. Speidl, S. Demyanets, S.P. Kastl, K.A. Krychtiuk, A. Wonnerth, G. Zorn, I. Tentzeris, S. Farhan, G. Maurer, J. Wojta*, K. Huber. G-CSF predicts cardiovascular events in patients with stable coronary artery disease. **PLoS One** **10**: e0142532, 2015
255. P.J. Hohensinner, C. Kaun, E. Buchberger, S. Demyanets, I. Huk, W. Eppel, G. Maurer, K. Huber, J. Wojta. Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells. **Biochim. Biophys Acta Mol. Cell Res.** **1863**: 360-367, 2015
256. G. Goliash, F. Wiesbauer, H. Blessberger, S. Demyanets, J. Wojta, K. Huber, G. Maurer, M. Schillinger, W.S. Speidl. Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. **J. Clin. Lipidol.** **9**: 801-806, 2015
257. A. Wonnerth, K.A. Krychtiuk, F.J. Mayer, E. Minar, J. Wojta, M. Schillinger, R. Koppensteiner, M. Hoke. Red cell distribution width and mortality in carotid atherosclerosis. **Eur. J. Clin. Invest.** **46**: 198-204, 2015
258. J. Wojta. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. **Eur. Heart J. – Cardiovasc. Pharmacother.** **2**: 106-107, 2016

259. F. Ahlin, J. Arfvidsson, K.G. Vragas, S. Stojkovic, K. Huber, J. Wojta*. MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. **Vasc. Pharmacol.** **81**: 15-21, 2016
260. M.P. Winter, F. Wiesbauer, A. Alimohammadi, H. Blessberger, N. Pavo, M. Schillinger, K. Huber, J. Wojta, I.M. Lang, G. Maurer, G. Goliash. Soluble galectin-3 is associated with premature myocardial infarction. **Eur. J. Clin. Invest.** **46**: 386-391, 2016
261. W. Eilenberg, S. Stojkovic, A. Piechota-Polanczyk, C. Kaun, S. Rauscher, M. Gröger, M. Klinger, J. Wojta, C. Neumayer, I. Huk, S. Demyanets. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. **Eur. J. Vasc. Endovasc. Surg.** **51**: 623-631, 2016
262. M. Enayati, M. Eilenberg, C. Grasl, P. Riedl, C. Kaun, B. Messner, I. Walter, R. Liska, H. Schima, J. Wojta, B.K. Podesser, H. Bergmeister. Biocompatibility assessment of a new biodegradable vascular graft via in vitro co-culture approaches and in vivo model. **Ann. Biomed. Eng.** 2016 in press
263. P.J. Hohensinner, B. Ebenbauer, C. Kaun, G. Maurer, K. Huber, J. Wojta. Reduced Ang2 expression in aging endothelial cells. **Biochem. Biophys. Res. Commun.** 2016 in press
264. S. Stojkovic, C. Kaun, J. Basilio, S. Rauscher, L. Hell, K.A. Krychtiuk, C. Bonstingl, R. de Martin, M. Gröger, C. Ay, W. Holnthoner, W. Eppel, C. Neumayer, I. Huk, K. Huber, S. Demyanets, J. Wojta. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. **Sci. Rep.** 2016 in press

*corresponding author

§shared senior author